197 related articles for article (PubMed ID: 24206882)
1. Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India.
Seth A; Hiremath S; Dani S; Kapoor S; Jain RK; Abhaichand R; Trivedi S; Kaul U; Patil A; Khemnar B; Rangnekar H
Indian Heart J; 2013; 65(5):586-92. PubMed ID: 24206882
[TBL] [Abstract][Full Text] [Related]
2. One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India.
Mehta AB; Chandra P; Dalal J; Shetty P; Desai D; Chocklingam K; Prajapati J; Kumar P; Magarkar V; Vasawada A; Goyal BK; Kumar V; Rao VS; Babu R; Parikh P; Kaul U; Patil A; Mhetre T; Rangnekar H
Indian Heart J; 2013; 65(5):593-9. PubMed ID: 24206883
[TBL] [Abstract][Full Text] [Related]
3. Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview.
Goyal BK; Kalmath BC; Kawar R; Sharma A; Khemnar B; Rangnekar H
Indian Heart J; 2013 Dec; 65(6):678-82. PubMed ID: 24407537
[TBL] [Abstract][Full Text] [Related]
4. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.
Urban P; Valdés M; Menown I; Eberli F; Alhaddad I; Hildick-Smith D; Iosseliani D; Roffi M; Oldroyd K; Kalloudi E; Eerdmans P; Berland J; Kleber FX;
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1151-60. PubMed ID: 25683225
[TBL] [Abstract][Full Text] [Related]
5. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
[TBL] [Abstract][Full Text] [Related]
6. Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy.
Wykrzykowska JJ; Serruys PW; Onuma Y; de Vries T; van Es GA; Buszman P; Linke A; Ischinger T; Klauss V; Corti R; Eberli F; Wijns W; Morice MC; di Mario C; van Geuns RJ; Juni P; Windecker S
JACC Cardiovasc Interv; 2009 Sep; 2(9):861-70. PubMed ID: 19778775
[TBL] [Abstract][Full Text] [Related]
7. Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes.
Menown IBA; Mamas MA; Cotton JM; Hildick-Smith D; Eberli FR; Leibundgut G; Tresukosol D; Macaya C; Copt S; Slama SS; Oldroyd KG
J Interv Cardiol; 2021; 2021():6654515. PubMed ID: 33880087
[TBL] [Abstract][Full Text] [Related]
8. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
9. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
[TBL] [Abstract][Full Text] [Related]
10. Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial.
Ghione M; Wykrzykowska JJ; Windecker S; Serruys PW; Buszman P; Linke A; Sohn HY; Corti R; Antoni D; Wijns W; Estevez-Loureiro R; Morice MC; Van Es GA; van Geuns RJ; Juni P; Eerdmans P; De Vries T; Konik S; Di Mario C
Cardiol J; 2016; 23(6):626-636. PubMed ID: 27665852
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
[TBL] [Abstract][Full Text] [Related]
12. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
13. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
14. Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population.
Wiebe J; Gilbert F; Dörr O; Liebetrau C; Wilkens E; Bauer T; Elsässer A; Möllmann H; Hamm CW; Nef HM
Catheter Cardiovasc Interv; 2015 Nov; 86(6):975-81. PubMed ID: 26269391
[TBL] [Abstract][Full Text] [Related]
15. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents.
Billinger M; Räber L; Hitz S; Stefanini GG; Pilgrim T; Stettler C; Zanchin T; Pulver C; Pfäffli N; Eberli F; Meier B; Kalesan B; Jüni P; Windecker S
Am Heart J; 2012 May; 163(5):876-886.e2. PubMed ID: 22607867
[TBL] [Abstract][Full Text] [Related]
17. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
[TBL] [Abstract][Full Text] [Related]
18. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy.
Wykrzykowska JJ; Räber L; de Vries T; Bressers M; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Regar E; Jüni P; Windecker S; Serruys PW
EuroIntervention; 2009 Aug; 5(3):310-7. PubMed ID: 19736154
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry.
Akin I; Nienaber CA; Richardt G; Tölg R; Hochadel M; Schneider S; Senges J; Tebbe U; Zeymer U; Sabin G; Kuck KH; Bergmann MW
Clin Res Cardiol; 2014 May; 103(5):363-72. PubMed ID: 24468896
[TBL] [Abstract][Full Text] [Related]
20. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients - results from the BELLO (balloon elution and late loss optimization) trial.
Giannini F; Latib A; Jabbour RJ; Costopoulos C; Chieffo A; Carlino M; Montorfano M; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Colombo A
Cardiovasc Revasc Med; 2017; 18(1):4-9. PubMed ID: 28011243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
